

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number  
WO 01/21656 A3

(51) International Patent Classification<sup>7</sup>: C07K 14/32,  
19/00, 14/25, A61K 39/07, 48/00, 39/108

(21) International Application Number: PCT/US00/26192

(22) International Filing Date:  
22 September 2000 (22.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/155,961 24 September 1999 (24.09.1999) US

(71) Applicant (for all designated States except US): THE  
GOVERNMENT OF THE UNITED STATE OF  
AMERICA, as represented by THE SECRETARY, DE-  
PARTMENT OF HEALTH AND HUMAN SERVICES  
[US/US]; Office of Technology Transfer, 6011 Executive  
Boulevard, Suite 325, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEPPLA, Stephen,  
H. [US/US]; 9501 Starmont Road, Bethesda, MD 20817  
(US). LIU, Shi-Hui [CN/US]; 1001 Rockville Pike #1822,  
Rockville, MD 20852 (US). NETZEL-ARNETT, Sarah

[US/US]; 17100 Dowing Street, #201, Gaithersburg, MD  
20877 (US). HANSEN-BIRKEDAL, Henning [DK/US];  
2 West Drive, Bethesda, MD 20814 (US). BUGGE,  
Thomas [DK/US]; 9802 Bristo Square Lane, #302,  
Bethesda, MD 20814 (US).

(74) Agents: PARENT, Annette, S. et al.; Townsend and  
Townsend and Crew LLP, 8th floor, Two Embarcadero  
Center, San Francisco, CA 94111-3834 (US).



(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

[Continued on next page]

(54) Title: MUTATED ANTHRAX TOXIN PROTECTIVE ANTIGEN PROTEINS THAT SPECIFICALLY TARGET CELLS  
CONTAINING HIGH AMOUNTS OF CELL-SURFACE METALLOPROTEINASES OR PLASMINOGEN ACTIVATOR  
RECEPTORS



(57) Abstract: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.